To report on the FDA approval of deucravacitinib for the treatment of adults with active psoriatic arthritis.
Key Findings:
Deucravacitinib achieved ACR20 response in 54% of patients in both trials compared to 34% and 39% in placebo groups.
ACR50 responses were 24% vs 14% and 29% vs 16% for deucravacitinib vs placebo in the two trials respectively.
ACR70 responses were 12% vs 5% and 10% vs 5% for deucravacitinib vs placebo.
Minimal disease activity was achieved by a greater proportion of patients receiving deucravacitinib.
Interpretation:
Deucravacitinib is the first TYK2 inhibitor approved for psoriatic arthritis, showing significant efficacy in improving disease activity compared to placebo.
Limitations:
The trials included only adults aged 18 years or older with active PsA.
POETYK PsA-1 participants had not previously received biologic DMARDs, while POETYK PsA-2 included patients with prior TNF inhibitor exposure.
Conclusion:
Deucravacitinib represents a new therapeutic option for adults with active psoriatic arthritis, demonstrating improved outcomes in clinical trials.
